SCHEMBL9930459

SCHEMBL9930459

COc1ccc(CNc2ncnc3c(C(=O)O)sc(C)c23)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 14/20 0.48
CYP3A4 P08684 14/20 0.48
CYP2C19 P33261 14/20 0.48
CYP2D6 P10635 12/20 0.48
ALDH1A1 P00352 10/20 0.48
HSD17B10 Q99714 9/20 0.48
CLK4 Q9HAZ1 8/20 0.48
LMNA P02545 8/20 0.48
MAPK1 P28482 5/20 0.48
USP2 O75604 4/20 0.48
TSHR P16473 9/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
ALOX15 P16050 3/20 0.48
KDM4C Q9H3R0 1/20 0.48
MAPT P10636 3/20 0.47
AURKA O14965 1/20 0.47
RPS6KB1 P23443 1/20 0.47
CYP2C9 P11712 7/20 0.47
HIF1A Q16665 5/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9930607 0.89 MAPT (0.56) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL9930740 0.81 CYP1A2 (0.55) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL30401719 0.79 KDM4C (0.52) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL24399771 0.79 KDM4C (0.52) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL9930489 0.78 KDM4C (0.53) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL1461787 0.77 AURKA (0.71) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL30401701 0.77 AURKA (0.71) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL31456984 0.76 KDM4C (0.52) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL21174364 0.76 KDM4C (0.52) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL24399556 0.75 AURKA (0.55) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed
WO-2011025940-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF CYP1A2 2189/4885CYP3A4 2785/4885CYP2C19 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.